-
公开(公告)号：US09850240B2
公开(公告)日：2017-12-26
申请号：US15101044
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D471/04 , A61K31/506 , A61K31/437 , A61K31/5377
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/5377
Abstract: A series of substituted [1,2,4]triazolo[4,3-a]pyridine derivatives, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09815797B2
公开(公告)日：2017-11-14
申请号：US15101283
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Gregory Foulkes , Martin Clive Hutchings , Victoria Elizabeth Jackson , Boris Kroeplien , James Thomas Reuberson , Sarah Margaret Rook , Zhaoning Zhu
IPC: C07D239/74 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/506 , A61K31/517 , C07D215/14 , C07D237/28 , A61K31/502 , C07D215/06 , C07D237/32 , C07D241/44 , A61K45/06 , C07D217/16 , C07D241/42 , C07D403/04
CPC classification number: C07D239/74 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/502 , A61K31/506 , A61K31/517 , A61K45/06 , C07D215/06 , C07D215/14 , C07D217/16 , C07D237/28 , C07D237/32 , C07D241/42 , C07D241/44 , C07D403/04 , A61K2300/00
Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09738710B2
公开(公告)日：2017-08-22
申请号：US14547291
申请日：2014-11-19
Applicant: UCB Biopharma SPRL
Inventor： Karen Margrete Miller , Marc Roger De Ryck , Christian Gilbert J. Wolff , Alastair David Griffiths Lawson , Helene Margaret Finney , Terence Seward Baker
CPC classification number: C07K16/18 , C07K16/28 , C07K2317/34
Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
-
公开(公告)号：US09499603B2
公开(公告)日：2016-11-22
申请号：US14802076
申请日：2015-07-17
Applicant: UCB Biopharma SPRL
Inventor： Kerry Louise Tyson
IPC: C07K16/00 , C07K14/705 , C07K16/28
CPC classification number: C07K14/70503 , C07K16/2818 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.
-
公开(公告)号：US09476081B2
公开(公告)日：2016-10-25
申请号：US14451975
申请日：2014-08-05
Applicant: UCB PHARMA S.A.
Inventor： Katharine Lacy Cain , Shirley Jane Peters , Paul Edward Stephens
CPC classification number: C12P21/00 , C07K14/47 , C07K16/00 , C07K16/18 , C07K16/40 , C12N9/0004 , C12P21/02 , Y02P20/52
Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
-
Patent Agency Ranking
公开(公告)号：US09394357B2
公开(公告)日：2016-07-19
申请号：US11910612
申请日：2006-04-04
Applicant: Alastair David Griffiths Lawson
Inventor： Alastair David Griffiths Lawson
IPC: C07K16/00
CPC classification number: C07K16/00 , C07K2317/56 , C07K2317/565 , C07K2317/92
Abstract: A method of obtaining at least one recombinant antibody with improved affinity for a selected antigen from a family of antibodies which bind the selected antigen comprising: a) obtaining a family of two or more antibodies which bind the same antigen in which the VH CDR3 amino acid sequence of each antibody in the family is the same length and greater than 60% identical at the amino acid level; b) re-pairing the VH region of an antibody obtained in step (a) with the VL region from a different antibody obtained in step (a) to produce a new recombinant antibody; and c) screening the recombinant antibody produced in step (b) and selecting said antibody if it has improved affinity for the selected antigen compared to any one of the antibodies obtained in step (a).
Abstract translation: 一种从结合所选抗原的抗体家族获得至少一种对所选抗原亲和力的重组抗体的方法，包括：a）获得结合相同抗原的两个或多个抗体的家族，其中所述抗体的VH CDR3氨基酸 家族中每种抗体的序列与氨基酸水平相同，长度大于60％; b）将步骤（a）中获得的抗体的VH区与来自步骤（a）中获得的不同抗体的VL区重新配对以产生新的重组抗体; 和c）筛选步骤（b）中产生的重组抗体，如果与步骤（a）中获得的任何一种抗体相比，对所选择的抗原具有改善的亲和力，则选择所述抗体。
-
公开(公告)号：US20160068586A1
公开(公告)日：2016-03-10
申请号：US14802076
申请日：2015-07-17
Applicant: UCB Biopharma SPRL
Inventor： Kerry Louise Tyson
IPC: C07K14/705
CPC classification number: C07K14/70503 , C07K16/2818 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.
Abstract translation: 结合包含重链和轻链的人PD-1的人源化激动抗体，其中重链的可变结构域包含SEQ ID NO：1中针对CDR-H1给出的序列，SEQ ID NO：2中给出的序列 对于CDR-H2和CDR-H3的SEQ ID NO：3中给出的序列，轻链的可变结构域包含SEQ ID NO：4中针对CDR-L1给出的序列，SEQ ID NO：5中给出的序列 对于CDR-L2和针对CDR-L3的SEQ ID NO：7中给出的序列。 本发明还延伸到抗体分子的治疗用途，用于产生所述抗体分子的组合物和方法。
-
公开(公告)号：US20160039929A1
公开(公告)日：2016-02-11
申请号：US14795374
申请日：2015-07-09
Applicant: UCB Biopharma SPRL
Inventor： Richard Evan Gelinas , Mitra Choudhury Singhal , Yi Zhang , Andrew George Popplewell , Ralph Adams
IPC: C07K16/24
CPC classification number: A61K39/3955 , A61K2039/505 , C07K16/248 , C07K2316/96 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-6的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号：US09234037B2
公开(公告)日：2016-01-12
申请号：US13523104
申请日：2012-06-14
Applicant: Terence Seward Baker
Inventor： Terence Seward Baker
IPC: C12N5/07 , A61K39/395 , A61K39/00 , A61K38/12 , C07K16/00 , C07K16/28 , C07K14/705
CPC classification number: A61K39/0005 , A61K2039/545 , A61K2039/6081 , A61K2039/62 , C07K14/705 , C07K16/28 , C07K2317/14 , C07K2317/20 , C07K2317/76
Abstract: The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.
-
公开(公告)号：US20150203486A1
公开(公告)日：2015-07-23
申请号：US14414287
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Praful Tulshi Chovatia , Anne Marie Foley , Ellen Olivia Gallimore , Laura Jane Gleave , Alexander Heifetz , Helen Tracey Horsley , Martin Clive Hutchings , Victoria Elizabeth Jackson , James Andrew Johnson , Craig Johnstone , Boris Kroeplien , Fabien Claude Lecomte , Deborah Leigh , Martin Alexander Lowe , James Madden , John Robert Porter , Joanna Rachel Quincey , Laura Claire Reed , James Thomas Reuberson , Anthony John Richardson , Sarah Emily Richardson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: C07D471/04 , A61K31/496 , A61K31/506 , C07D491/107 , A61K31/5377 , A61K31/5513 , A61K31/554 , A61K31/437 , A61K31/541
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107 , C07D519/00
Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列式（I）的咪唑并[1,2-a]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
-
-
-
-
-
-
-
-
Search Results
175
records
(took 0.046 seconds)
